Biogen

Update in progress

BIIB (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Biogen discovers, develops, manufactures and markets therapies worldwide for neurological and autoimmune diseases. Its portfolio includes MS drugs TECFIDERA, AVONEX, PLEGRIDY and TYSABRI; SPINRAZA for spinal muscular atrophy; LEQEMBI for Alzheimer's; SKYCLARYS, QALSODY, FUMADERM, ZURZUVAE; anti-CD20 medicines RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO and glofitamab; and several biosimilars. The company collaborates with many partners and was founded in 1978 in Cambridge, MA.

Company score

Sentiment: 1.91; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.21; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.89; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.63; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive